| abstract |
The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (1)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development. |